Six new licensing deals for drug and gene therapy development firm
Oxford Genetics has won six new licensing deals for its scalable drug and gene therapy manufacturing in the synthetic biology sector...
List view / Grid view
Oxford Genetics has won six new licensing deals for its scalable drug and gene therapy manufacturing in the synthetic biology sector...
Particle Measuring Systems expands support to ensure monitoring system operations...
A New Drug Application has been made to the US Food and Drug Administration for the drug darolutamide to treat non-metastatic prostate cancer...
Strong regimentation and economic interests demand the development and implementation of new techniques for process control and analysis in the pharmaceutical industry. The extensive analysis of all deployed materials, intermediates and products leads to a higher degree of process stability and can contribute to a faster compensation for deviations, especially…
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
The Bio-Process Systems Alliance, the primary international industry association for single-use bio-processing, is pleased to announce the release of its latest whitepaper...
General Electric is selling its biopharma business for $21.4 billion, with shares in the company jumping 16 percent upon the news...
In this edition of our 'Guide to' series we look at analytical testing instruments from SUEZ.
A method commonly used in lithium-ion batteries has been developed to help the safer and cheaper manufacture of medicines...
The EU is adopting new rules which should boost the competitiveness of EU producers of generic medicines and biosimilar products...
A study has shown that a 'smart drug' that delivers a toxic payload directly to tumour cells could be a possible treatment for breast cancer...
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...
A study has shown how structural barriers are one of the main reasons why clinical trials often do not meet their enrolment targets...
Eurofins CDMO provides a full suite of drug development services encompassing development of the bioprocesses, formulation screening, analytical development, pre-clinical testing, sterile and non-sterile bio-manufacturing of clinical trial batches and orphan drugs.
A study has found that the FDA failed to design and implement an effective monitoring program for Transmucosal Immediate-Release Fentanyls...